EZR and muscular atrophy: In summary, under the premise of considering hereditary muscular atrophy disease, especially L-periaxin deletion or mutation, combined gene therapy targeting Ezrin with L-periaxin could be a novel and potential clinical strategy for the treatment of muscular atrophy caused by a variety of pathological factors, especially nerve injury (Fig. 9).